drugset / Trial / NCT04453852
Monovalent Recombinant COVID19 Vaccine
Phase 1
Completed
40 enrolled
Vaxine Pty Ltd
Central Adelaide Local Health Network Incorporated · collab
RandomizedParallel-groupTriple-blindPrevention
Summary
This is a study to test a new vaccine (Covax-19) against COVID-19. COVID-19 is a potentially deadly disease that is caused by a new strain of coronavirus called SARS-CoV-2. To date, SARS-CoV-2 has infected over 4 million people worldwide resulted in the deaths of over three hundred thousand people.
Timeline
- Start
- 2020-06-30
- Primary completion
- 2021-02-01
- Completion
- 2021-04-14
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Spikogen | Vaccine | 25 ug | Intramuscular |
| Subject | Spikogen | Vaccine | 15 mg | Intramuscular |